Cardiac hypertrophy is initiated as an adaptive response to sustained overload but progresses pathologically as heart failure ensues 1 . Here we report that genetic loss of APJ, a G-protein-coupled receptor, confers resistance to chronic pressure overload by markedly reducing myocardial hypertrophy and heart failure. In contrast, mice lacking apelin (the endogenous APJ ligand) remain sensitive, suggesting an apelin-independent function of APJ. Freshly isolated APJ-null cardiomyocytes exhibit an attenuated response to stretch, indicating that APJ is a mechanosensor. Activation of APJ by stretch increases cardiomyocyte cell size and induces molecular markers of hypertrophy. Whereas apelin stimulates APJ to activate Ga i and elicits a protective response, stretch signals in an APJ-dependent, G-protein-independent fashion to induce hypertrophy. Stretchmediated hypertrophy is prevented by knockdown of b-arrestins or by pharmacological doses of apelin acting through Ga i . Taken together, our data indicate that APJ is a bifunctional receptor for both mechanical stretch and the endogenous peptide apelin. By sensing the balance between these stimuli, APJ occupies a pivotal point linking sustained overload to cardiomyocyte hypertrophy.
G-protein-coupled receptors (GPCRs) have been widely implicated in the control of cardiac function. These receptors couple to heterotrimeric GTP-binding proteins of the Ga s , Ga i , Ga q/11 and Ga 12/13 families, and transduce the GPCR signal to intracellular targets. Numerous studies have linked Ga s to increased contractility, Ga q/11 to pathological hypertrophy 2, 3 and Ga i to cardioprotection 4 . APJ is a GPCR identified as the receptor for the adipokine apelin 5, 6 . Apelinactivated APJ signals through Ga i , exerting a positive effect on cardiac contractility [7] [8] [9] and a vasodilator activity that counteracts angiotensin-II-induced atheroma 10, 11 . Apelin administration blunts progression to hypertrophy ( Supplementary Fig. 1 and Supplementary Tables 2 and  3 ) and apelin-KO mice show susceptibility to heart failure 12 (also see Supplementary Fig. 1 and Supplementary Table 1 ). Thus, apelin and its receptor APJ are emerging as potential therapeutic targets.
We examined the response of APJ knockout (APJ-KO) mice to sustained pressure overload by transaortic constriction (TAC). Although deletion of APJ resulted in some prenatal lethality 13, 14 , all viable APJ-KO mice showed normal adult appearance and cardiovascular parameters at baseline ( Supplementary Table 4 ). However, APJ-null animals were resistant to the pathological hypertrophic response to TAC ( Fig. 1a-d ) observed both in wild type (WT) and in apelin-KO mice ( Supplementary Fig. 1g -i). APJ-KO mice responded to TAC by initially increasing cardiac mass, but the maladaptive progression to dilated ventricular hypertrophy was blunted shortly after injury (Supplementary Table 4 ). The protective effect persisted longterm ( Fig. 1a , b, g, h) in all parameters measured, including diminished cardiomyocyte size ( Fig. 1c, d ), reduced fibrosis ( Fig. 1e, f . f, Quantification of e. g, Fractional shortening (FS%) decreased in WT mice after TAC, but did not change significantly in the APJ-KO mice. APJ-KO mice fail to develop heart failure upon sustained TAC as shown by echocardiographyc analysis. h, Heart weight/body weight ratio (HW/BW) at baseline and in TAC-operated mice, 90 days after surgery (see Supplementary  Table 4 for details). Error bars, s.e.m.*P , 0.05 between indicated groups, analysis of variance. and WT) ( Fig. 1g and Supplementary Tables 1 and 4 ). In summary, both WT and apelin-KO mice presented clear signs of heart failure after 90 days of TAC, whereas APJ-KO mice were almost unaffected. The maintenance of cardiac function in the APJ-KO demonstrates that the expression of APJ is necessary to elicit heart failure in response to pressure overload.
The different responses of apelin-KO and APJ-KO mice to TAC imply that either apelin can act independently of APJ, or that APJ transduces a signal independently of apelin. We tested the first hypothesis by infusing APJ-KO mice with apelin (285 mg kg 21 per 24 h) and examining two readouts: contractility under TAC and vascular tone. Notably, apelin infusion did not increase cardiac contractility (percentage fractional shortening) in TAC-APJ-KO mice, in contrast to the characteristic improvement seen in TAC-WT animals ( Supplementary Fig. 2a ). In the absence of apelin infusion, endogenous levels of apelin in blood increased after TAC from 1 to 2 ng ml 21 and that rise was not different in WT and APJ-KO mice, making it unlikely that the protection achieved in the APJ-KO is due to hyper-activation of apelin signalling ( Supplementary Fig. 2b ). To test vascular tone, systolic and diastolic blood pressures were increased by infusion of Ang-II (1,000 ng kg 21 min 21 ). Apelin infusion significantly decreased systolic blood pressure in WT animals but not in APJ-KO mice ( Supplementary Fig. 2c -f), further indicating that apelin activity requires APJ.
Because the mechanical properties of the heart change markedly during pressure overload 15 , and the structurally related angiotensin receptor (AT-1) can act as a mechanosensor 16 , we asked whether APJ responds to mechanical stretch. Initially these experiments were challenging as cultured cardiomyocytes consistently downregulate the expression of endogenous APJ ( Supplementary Fig. 3a ), and studies had to be restricted to freshly isolated adult cardiomyocytes. We mimicked the effect of pressure overload by using a carbon fibre technique 17 to stretch cardiomyocytes and evaluated their Frank-Starling gain (FSG). FSG is a dimensionless metric of the force that can be recruited by stretch 18 . Freshly isolated adult cardiomyocytes from WT mice showed a significantly higher FSG than cardiomyocytes from APJ-KO mice ( Fig. 2a-c) . Treatment with apelin decreased the FSG in WT cardiomyocytes but showed no effect in APJ-KO cells (Fig. 2d ). Therefore, apelin modulated the response to stretch only in cardiomyocytes with APJ receptors.
Engineered cells stably expressing human APJ (APJ-HEK) responded to apelin by increasing the content of phosphorylated extracellular signal-regulated kinase (pERK) (Fig. 3a, b) whereas parental (HEK) cells showed no significant change. Stretch also increased pERK content in cells expressing APJ (Fig. 3a, b ). pERK levels, therefore, reflect the cellular response to APJ activation by either stretch or apelin. pERK was therefore used as a simple readout of APJ activation. The Ga i inhibitor PTX blocked the ability of apelin, but not stretch, to induce APJ-dependent phosphorylation of ERK ( Fig. 3a, b) , first suggesting that separate mechanisms link stretch and apelin to APJ intracellular signalling. 
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We next examined whether activation of APJ by stretch or apelin differentially modulates G-protein-generated second messengers. Activation of Ga i is associated with inhibition of adenyl-cyclase and reduced cAMP, whereas activation of Ga s increases cAMP 19 . cAMP did not increase after application of stretch or apelin, arguing against activation of adenyl-cyclase (and Ga s ) ( Fig. 3c, d , no isoproterenol conditions). In contrast, when isoproterenol was used to elevate the intracellular concentration of cAMP 20 , apelin addition decreased cAMP levels in the APJ-HEK cells (Fig. 3c ). This effect of apelin was partly inhibited by PTX, consistent with the involvement of Ga i (Fig. 3c ). Apelin did not modify isoproterenol-stimulated cAMP formation in untransfected HEK controls, showing that the decrease is mediated by APJ. These data agree with previous reports 21 and demonstrate that Ga i transduces the signal initiated by apelin binding to APJ. In contrast, stretch reduced cAMP in parental HEK as well as in APJ-HEK cells (Fig. 3d ), indicating that, although stretch can activate Ga i signalling, this response is not mediated through APJ.
The Ga 16 subunit couples any activated GPCR to phospholipase C, which results in accumulation of inositol phosphates (IP1), and thus provides a general readout of G-protein activation 22 . Stretch did not 
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increase IP1 production whereas apelin did so in a dose-responsive manner (Fig. 3e) . Notably, for any given concentration of apelin, stretch consistently reduced G-protein activation (Fig. 3e ). There was a decrease in maximal levels and a shift in half-maximum effective concentration (EC 50 ) from 5.1 3 10 29 to 5.5 3 10 28 when both stimuli were applied simultaneously (Fig. 3e) . These experiments demonstrate that APJ activation by stretch is largely G-protein independent and that stretch interferes with apelin-mediated G-protein activation by APJ. Using a b-arrestin/APJ complementation assay, apelin was found to induce a dose-dependent increase in b-arrestin signalling, as expected (Fig. 3f) . Stretch in the absence of apelin boosted b-arrestin signalling twofold more than baseline (Fig. 3g ). Notably, stretch increased b-arrestin recruitment in response to apelin at all doses tested (Fig. 3g) . Taken together, stretch causes APJ to signal less effectively/ potently through G proteins, but to recruit b-arrestin more effectively.
To investigate whether these distinct mechanisms of APJ action differentially affect cardiac hypertrophy, we examined cardiomyocyte cell growth and the expression of molecular markers of pathological hypertrophy in neonatal rat ventricular cardiomyocytes 23, 24 . These cardiomyocytes in culture respond to mechanical stretch 25 , mainly through the angiotensin II receptor AT-1 26 and the endothelin1 receptor ET-A 27 , which are also GPCRs. To test the specific effect of APJ in cardiac stretch/hypertrophy, we used pharmacological inhibitors of AT-1 (100 nM candesartan) and ET-A (300 nM BQ123), hereafter labelled as 'inhibitors'. To overcome APJ downregulation during cardiomyocyte culture, we re-established APJ expression by adenoviral transduction (about 90% efficiency) with either control GFP (Ad-GFP) or an APJ-GFP fusion protein (Ad-APJ-GFP). Hypertrophy was assessed by the characteristic increase in perinuclear immunolocalization of atrial natriuretic factor (ANF) ( Fig. 4a-m) . Remarkably, apelin treatment did not increase ANF immunostaining, neither in Ad-APJ-GFP-nor in Ad-GFP-infected cells ( Fig. 4d-f, m) . In contrast, stretch applied in the presence of inhibitors significantly increased the number of perinuclear ANF 1 cells in APJ-restored cardiomyocytes (27 6 1%), but not in control cardiomyocytes infected with Ad-GFP (5.8 6 2.1%) ( Fig. 4g-i, m) . Co-stimulation with apelin and stretch reduced the number of ANF 1 cells ( Fig. 4j-l, m) . Stretch also induced specific changes in the expression of other molecular markers of hypertrophy, including an increased ratio of bto a-myosin heavy chain (b-MHC/a-MHC) ( Fig. 4n ) and increased cell size (Fig. 4o ). Similar to its effects on ANF, the addition of apelin also attenuated effects of stretch on other parameters of hypertrophy ( Fig. 4m-o) . The induction of ANF by stretch was PTX insensitive, but the ability of apelin to antagonize stretchinduced hypertrophy was prevented by treatment with PTX ( Fig. 4w) .
Several control experiments confimed that APJ is directly involved in the response to stretch: neonatal rat ventricular cardiomyocytes treated with forskolin responded to apelin only upon reconstitution of APJ expression, as monitored by their ability to decrease intracellular cAMP levels (Fig. 4p ). The possibility that stretch induces the secretion of factors that might indirectly activate hypertrophy through APJ was considered but seems unlikely because conditioned medium from APJ-transfected cardiomyocytes did not induce ANF expression ( Fig. 4q) . Moreover, the concentration of apelin in the media remained unchanged (approximately 5 ng ml 21 ) with or without stretch (Fig. 4r) , and conditioned media from stretched cells could not activate b-arrestin recruitment (Fig. 4s ). Single-cell analysis of low multiplicity APJ-GFP transduced cells showed that cardiomyocytes require APJ to induce ANF upon stretch ( Fig. 4t -v, note perinuclear ANF immunostaining only in GFP 1 cells in panel v), further demonstrating that APJ activation through stretch is sufficient to elicit cardiac hypertrophy. Previous studies showed that APJ interacts with AT-1 and apelin antagonizes AT-1 function 11 . As shown in Fig. 4x , in the presence of AT-1 inhibitors, only those cells expressing APJ responded to stretch by significantly increasing perinuclear ANF expression. In the absence of AT-1 inhibitors, APJ-transduced and non-transduced cells reached the same maximal level of ANF expression ( Fig. 4y) . Thus, blocking AT-1 does not impair the ability of APJ to respond to stretch, indicating that APJ alone is sufficient to transduce a stretch-induced hypertrophy signal.
Notably, siRNA specific for b-arrestin1 or b-arrestin2 (Fig. 4z ) blocked the stretch induction of hypertrophic markers (b-MHC/a-MHC ( Fig. 4z ) and ANF (not shown)) with an additive effect when both siRNAs were used together. These data substantiate the model that APJ signalling through b-arrestin mediates stretch-induced myocardial hypertrophy.
In summary, the mechano-response of APJ is necessary (blunted hypertrophic response to TAC of APJ-KO mice, Fig. 1 ) and sufficient (stretch induction of ANF expression occurs in cells expressing APJ, Fig. 4 ) to trigger myocardial hypertrophy in a b-arrestin-dependent manner (Fig. 4z ). Apelin does not induce hypertrophy, but instead blunts stretch-mediated hypertrophy (Fig. 4j-o ), suggesting the ability of apelin to override pathological signalling from stretch. At a mechanistic level, APJ transduces apelin and stretch signalling differently. The response to apelin seems to be G-protein-PTX sensitive, whereas that induced by stretch is PTX insensitive and G-protein independent in the absence of exogenous apelin (Fig. 3 ). Stretch profoundly affects apelin signalling, diminishing G-protein activation while augmenting b-arrestin recruitment ( Fig. 3e-g) . These data indicate that APJ integrates apelin and stretch stimuli, biasing the levels of G-protein signalling versus b-arrestin recruitment accordingly.
These results have implications for the consideration of APJ as a drug target, because APJ/stretch can be pathological. Therefore, a beneficial effect will be obtained not by general apelin receptor agonism, but rather by selectively inhibiting the ability of APJ to respond to mechanical stretch or by blocking its interaction with molecules that initiate pathological signalling cascades.
METHODS SUMMARY
All experiments were performed in accordance with relevant guidelines and regulations. The Sanford-Burnham Medical Research Institute's Animal Care & Use Program is accredited by Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International), and a Multiple Project Assurance A3053-1 is on file in the Office of Laboratory Animal Welfare, Department of Health and Human Services. APJ and apelin KO mice. APJ-KO mice were obtained from Deltagen. Apelin-KO mice are described elsewhere 13 . Both APJ and apelin lines (male and female) were in C57Bl/6 genetic background in a 99-100% purity, as demonstrated by microsatellite analysis (Radil). For detailed methods, see Supplementary Information.
